The global next generation sequencing market is projected to exhibit a significant growth, at a CAGR of around 16.4%, during the forecast period. The increasing adoption of personalized medicines for the treatment of cancer is augmenting the growth of the next generation sequencing technology market. Personalized medicine has the potential to modify therapy with the best response and highest safety margin to ensure better patient care. By enabling these medicines, each patient can receive earlier diagnoses, risk assessments, and optimal treatments. The personalized medicine holds promise for improving healthcare while lowering costs which is expected to be a positive indicator for the growth of the global next generation sequencing market.

Get Free Sample Copy @ https://www.omrglobal.com/request-sample/next-generation-sequencing-market

The personalized medicine is defined as a point of care in the treatment that is customized as per an individual patient. There have been several types of research going on presently to develop personalized medicine based on the patients. Several factors should be considered before providing personalized medicine to a patient. Primarily, the doctors must detect the type of diseases, such as cancer, or the symptoms of it that can be developed in a patient. Detection of cancer is important for the surgeon or the doctor to find the best-suited therapy that can treat the person.

A Full Report of Global Next Generation Sequencing Market is Available at: https://www.omrglobal.com/industry-reports/next-generation-sequencing-market

For developing of personalized medicine, several genetic tests need to be taken in account as these tests will eventually reveal the various conditions of the patients such as detection of the individual developing a specific type of cancer. The personalized medicine provides an approach to treat the patient based on the age, sex, type of cancer, the reaction towards a drug and other factors. As per the Personalized Medicine Coalition (PMC) 2017 report, around 42% of all compounds and around 73% of oncology compounds in the pipeline have the potential to be included in personalized medicines.

The biopharmaceutical companies closely doubled their R&D investment in personalized medicine over the past five years and suppose to increase their investment in the near future. The US FDA has received a significant number of personalized medicines for its approval in the past years. As per the US FDA data, the organization has approved around 21% of personalized medicines in 2014, which rammed up to 34% in 2017.

Global Next Generation Sequencing Market-Segmentation

By Product Type

Reagents and Kits
Instruments
Services

By Technology

Pyrosequencing
Sequencing by Synthesis (SBS)
Sequencing by Ligation (SBL)
Whole Genome Sequencing
RNA Sequencing
Targeted Resequencing
Others (Methyl Sequencing)

By Application

Drug Discovery
Genomic Research
Disease Diagnostics
Personalized Medicine
Others (Agricultural and Animal Research)

By End-User

Academic and Clinical Research Centers
Pharmaceutical and Biotechnology Companies
Contract Research Organizations (CRO)
Hospitals and Clinics

Global Next Generation Sequencing Market– Segment by Region

North America

United States
Canada

Europe

Germany
UK
France
Spain
Italy
Rest of Europe

Asia-Pacific

China
Japan
India
Rest of Asia-Pacific

Rest of the World

For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/next-generation-sequencing-market

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: [email protected]
Contact no: +1 646-755-7667, +91 780-304-0404